Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.63.
Several analysts have recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Canaccord Genuity Group upped their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th.
Check Out Our Latest Analysis on Taysha Gene Therapies
Institutional Trading of Taysha Gene Therapies
Taysha Gene Therapies Price Performance
TSHA stock opened at $1.73 on Thursday. The stock’s 50 day moving average price is $2.11 and its 200 day moving average price is $2.19. The firm has a market cap of $354.55 million, a P/E ratio of 2.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
- Five stocks we like better than Taysha Gene Therapies
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Work and Play: Investing in the Rise of Bleisure Travel
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.